
The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
Is selective serotonin reuptake inhibitor use associated with an increased risk of spontaneous intracranial hemorrhage?
A study published in
The study also compared SSRIs with tricyclic antidepressants, and examined whether or not anti-thrombotics modified the risk of hemorrhage.
SSRI use was associated with an increased risk of hemorrhage compared with tricyclics. Moreover, the risk was greatest in the first 30 days of use, and the relative risk was increased by anti-thrombotics.